Course Overview



This course will be held again on
April 26 - 30, 2021.

Information contained in this site is for the 2020 program.
Information for the 2021 program not yet available.

State-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases

This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven:

  • Strategies for optimal decision-making in the prevention, diagnosis, and treatment of infectious diseases
  • Newer antimicrobials and treatment strategies for highly resistant bacterial infections
  • COVID-19 (coronavirus disease 2019): the latest updates
  • Prevention and treatment of infection in immunocompromised hosts
  • State-of-the-art approaches to common infections
  • Clinical approaches to complex, rare, "don't-miss" infections
  • New, evolving, and emerging infectious diseases
  • Update on antifungal diagnostics and therapy
  • Optimal management of Staph aureus infections
  • Infections in persons with substance use disorders
  • What’s new in HIV prevention and management
  • Musculoskeletal infectious diseases 
  • ID for hospital medicine specialists

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.  

Highlights of the 2020 Program

Expanded Case-Based and Problem-Solving Education 

The 2020 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions in larger sessions as well as one-on-one with the national experts who will be providing updates at this event.

Treating Highly Resistant Infections, including:

  • MRSA, vancomycin-intermediate Staph aureus (VISA), and borderline oxacillin-resistant Staph aureus (BORSA)
  • Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
  • Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
  • Vancomycin-resistant enterococci (VRE) 
  • Resistant and difficult-to-treat fungal infections

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

  • Infections in the growing populations of immunocompromised hosts
  • Infections in pregnancy, including Zika
  • Infections in persons with substance use disorders
  • Infections of travelers and foreign-born persons
  • Systemic fungal infections
  • Native and device-related orthopedic infections
  • Central nervous system (CNS) infections
  • Ear, nose and throat (ENT) and eye infections
  • Bronchiectasis and pneumonia
  • HIV and its infectious and noninfectious complications
  • PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
  • Sexually transmitted infections
  • Hepatitis C monoinfection and coinfection
  • Tick- and mosquito-borne infections and zoonoses
  • Vaccines and vaccine-preventable infections
  • Clostridium difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

  • COVID-19 (coronavirus disease 2019)
  • EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
  • Re-emergence of vaccine-preventable diseases
  • Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
  • Candida auris infection
  • Global infectious diseases of clinical importance
  • Zoonoses—the old and the new

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

  • Selecting the best antimicrobial and duration of treatment
  • Rapid detection and empiric treatment of the life-threatening infectious diseases
  • Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral? 
  • Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop  

Our talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

  • Antimicrobial stewardship workshop (optional) to prevent resistance and reduce cost
  • Infection control, including biothreats
  • Early inpatient ID consultations to reduce mortality, length of stay, and cost
  • Outpatient Parenteral Antibiotic Therapy (OPAT): best practices in program design and operation
  • Strategies for management of infection in persons with substance use disorder
  • Curbside consultation and e-consultation


In 2020, we offer two optional pre-course workshops, giving you the option of in-depth, small-group learning about important topics in ID.

Please note: Seating is limited, and each workshop is available on a first-come, first-served basis.

Advanced Cases in Resistant and Difficult-to-Treat Infections
Monday, April 27, 1:00 - 3:15 pm


Antimicrobial Stewardship Programs (ASP): Updated Principles and Practice with Instructive Cases
Monday, April 27, 3:30 - 5:30 pm

For complete descriptions of these workshops, click here.